Prism AI Therapeutics provides a global SaaS platform for the development and commercialization of multi-omic diagnostic (Dx) and companion diagnostic (CDx) assets.

​

Our proprietary quantum mechanics-derived AI/ML is uniquely able to transform real-world noisy and high-dimensional multi-omic data into accurate, precise, actionable and mechanistically interpretable biomarkers from as few as 20 patients. Our predictors – of drug efficacy, toxicity, and targets – consistently validate and outperform all others, improving drug development success rates and expanding the patient addressable market. Our services are supported by an extensive network of molecular profiling lab partners.​